|Written||2014-04||Gizem Güpür, Mesut Muyan|
|Department of Biological Sciences, Middle East Technical University, Ankara, Turkey|
(Note : for Links provided by Atlas : click)
|Location||16p11.2 [Link to chromosome band 16p11]|
|Location_base_pair||Starts at 30092314 and ends at 30096200 bp from pter ( according to hg19-Feb_2009) [Mapping YPEL3.png]|
|Local_order||From telomere to centromere: MAPK3-GDPD3-LOC101928595-YPEL3-TBX6-PPP4C-ALDOA-FAM57B-C16orf92-DOC2A.|
|Local order of YPEL3 is shown together with leading and subsequent genes on chromosome 16.|
|Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)|
|YPEL3 (16p11.2) / EXD3 (9q34.3)|
|Boxes show exons; filled boxes correspond to coding exons, empty boxes indicate noncoding exons. Lines connecting the boxes represent introns. Arrows indicate the translation initiation codon.|
|Description||YPEL3 has 4 exons.|
|Transcription|| YPEL3 has 2 transcript variants, resulting from the differential processing of the exon 1.|
Transcript variant 1: 1588 bp mRNA (NCBI RefSeq NM_031477.4).
Transcript variant 2: 940 bp mRNA (NCBI RefSeq NM_001145524.1).
|Note|| Two transcript variants encode two protein isoforms differing at their amino-termini.|
Protein yippee-like 3 isoform 1; 157 aa protein (NCBI RefSeq NP_113665.3).
Protein yippee-like 3 isoform 2; 119 aa protein (NCBI RefSeq NP_001138996.1).
|Expression||In human, YPEL3 is expressed in the brain, heart, kidney, lung, pancreas, placenta, skeletal muscle, colon, ovary, leukocyte, prostate, small intestine, spleen, testis, thymus, bone marrow, leukocyte, tonsil, fetal brain, fetal heart, fetal kidney, fetal liver, fetal lung, fetal skeletal muscle, fetal spleen and fetal thymus (Hosono et al., 2004).|
|Localisation||Immunofluorescence staining with an antibody recognizing Ypel1, 2, 3 and 4 proteins suggests that Ypel1-4 are nuclear proteins. In interphase cells, Ypel1-4 are localized in nucleoli and the centrosome. In the mitotic phase, Ypel1-4 become localized on or close to the mitotic apparatus rather than in the centrosome (Hosono et al., 2004).|
|Function|| Studies show that the expression of YPEL3 gene is up-regulated during DNA damage, reflected as an increase in YPEL protein levels, likely through two functional p53 binding sites present on the YPEL3 gene promoter (Kelley et al., 2010).|
When YPEL3 is expressed by a tetracycline inducible system at levels comparable to endogenous mRNA levels detected upon DNA damage, both MCF7 and U2OS cells showed fewer colonies compared to uninduced cells. YPEL3 expressing U2OS and MCF7 cells also showed an increase in cellular senescence as shown by increases β-galactosidase activity and the appearance of foci within the nuclei of senescent cells (SAHF) (Kelley et al., 2010).
|Homology|| In human, YPEL3 has 4 paralogs; YPEL1, YPEL2, YPEL4 and YPEL5. Ypel3 has 88.2% aminoacid sequence identity with Ypel1; 89.1% with Ypel2; 83.9% with Ypel4 and 43.8% with Ypel5 (Hosono et al., 2004).|
Ypel3 is an ortholog of Drosophila Yippee protein and has 45.5% aminoacid sequence identity to Yippee. There are 100 YPEL family genes in 68 species including mammal, bird, amphibia, fish, protochordate, insect, nematode, coelenterate, echinoderm, protozoan, plant, and fungi. In this diverge range of organisms, YPEL family proteins show a high level of homology with many identical residues. Thus, a consensus sequence is deduced as follows: C-X2-C-X19-G-X3-L-X5-N-X13-G-X8-C-X2-C-X4-GWXY-X10-K-X6-E. In the consensus sequence, the number of non-consensus residues, designated as X, is identical for all species examined (Hosono et al., 2004).
4. Implicated in
|Note||YPEL3 is found to be down-regulated in 9 commercial colon tumor samples and in 22 patient colon adenocarcinoma (Tuttle et al., 2011).|
|Note||A significant decrease in YPEL3 mRNA levels was detected in 9 commercial and 30 patient ovarian tumors. In Cp70 ovarian cells, hypermethylation of a CpG island immediately upstream of the YPEL3 promoter is suggested to be the basis for the observed down-regulation (Kelley et al., 2010).|
|Note||YPEL3 mRNA is shown to be down-regulated in 8 of 9 commercial lung tumor samples (Tuttle et al., 2011).|
|Note|| YPEL3 is observed to be down-regulated in breast cancer cell models. Decrease in YPEL3 mRNA levels by siRNA causes an increase in the growth of estrogen receptor positive (ER+) MCF7 cells while YPEL3 over-expression decreases cell number. Moreover, YPEL3 mRNA as well as Ypel protein levels show an increase in MCF7 cells when 17β-estradiol (E2) is withdrawn. In contrast, the addition of E2 at a circulating level (1nM) decreases the expression of YPEL3. The down-regulation of YPEL3 by E2 can be reversed by the addition of selective estrogen receptor modulator, tamoxifen, TMX (Tuttle et al., 2012).|
In addition to p53, E2-ER signaling plays a role in the regulation of YPEL3 gene expression based on the observations that the reduction of intracellular ERa levels in MCF7 cells by ERa knockdown increases the expression of YPEL3 gene (Tuttle et al., 2012).
Studies also showed that when grown in the absence of E2, MCF7 cells undergo cellular senescence, whereas the silencing of YPEL3 rescues cells from senescence. Further evidence that YPEL3 is involved in E2-ER mediated cellular senescence was obtained from studies showing that the treatment of MCF7 cells with TMX increases the expression of the YPEL3 gene and that TMX-induced cellular senescence is not observed when YPEL3 is silenced. Importantly, cellular senescence induced by removal of E2 and/or over-expression of YPEL3 is independent of p53 expression. Thus, it appears that YPEL3 plays a role in E2-ER signaling dependent cellular growth and senescence in MCF7 cells. This in turn implies that Ypel3 is a tumor suppressor protein (Tuttle et al., 2012).
|Identification and characterization of a novel gene family YPEL in a wide spectrum of eukaryotic species.|
|Hosono K, Sasaki T, Minoshima S, Shimizu N.|
|Gene. 2004 Sep 29;340(1):31-43.|
|YPEL3, a p53-regulated gene that induces cellular senescence.|
|Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ.|
|Cancer Res. 2010 May 1;70(9):3566-75. doi: 10.1158/0008-5472.CAN-09-3219. Epub 2010 Apr 13.|
|Novel senescence associated gene, YPEL3, is repressed by estrogen in ER+ mammary tumor cells and required for tamoxifen-induced cellular senescence.|
|Tuttle R, Miller KR, Maiorano JN, Termuhlen PM, Gao Y, Berberich SJ.|
|Int J Cancer. 2012 May 15;130(10):2291-9. doi: 10.1002/ijc.26239. Epub 2011 Aug 9.|
|Senescence-associated gene YPEL3 is downregulated in human colon tumors.|
|Tuttle R, Simon M, Hitch DC, Maiorano JN, Hellan M, Ouellette J, Termuhlen P, Berberich SJ.|
|Ann Surg Oncol. 2011 Jun;18(6):1791-6. doi: 10.1245/s10434-011-1558-x. Epub 2011 Jan 26.|
|This paper should be referenced as such :|
|G Güpür, M Muyan|
|YPEL3 (yippee-like 3 (Drosophila))|
|Atlas Genet Cytogenet Oncol Haematol. 2015;19(1):38-40.|
|Free journal version : [ pdf ] [ DOI ]|
|On line version : https://atlasgeneticsoncology.usal.es/classic/Genes/YPEL3ID51528ch16p11.html|
|Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]|
7. External links
|REVIEW articles||automatic search in PubMed|
|Last year publications||automatic search in PubMed|
|© Atlas of Genetics and Cytogenetics in Oncology and Haematology||indexed on : Thu Jan 17 19:12:18 CET 2019|
For comments and suggestions or contributions, please contact us firstname.lastname@example.org.